{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T15:49:57Z","timestamp":1795016997136,"version":"4.10.1"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2023,5,5]],"date-time":"2023-05-05T00:00:00Z","timestamp":1683244800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,5,5]],"date-time":"2023-05-05T00:00:00Z","timestamp":1683244800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2023,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Allogeneic hematopoietic cell transplantation is a potentially curative treatment in high-risk acute lymphoblastic leukemia (ALL). Conditioning regimens based on \u226512 Gray total body irradiation (TBI) represent the current standard in patients \u226445 years, whereas elderly patients frequently receive intermediate intensity conditioning (IIC) to reduce toxicity. To evaluate the role of TBI as a backbone of IIC in ALL, a retrospective, registry-based study included patients &gt;45 years transplanted from matched donors in first complete remission, who had received either fludarabine\/TBI 8\u2009Gy (FluTBI8, <jats:italic>n<\/jats:italic>\u2009=\u2009262), or the most popular, irradiation-free alternative fludarabine\/busulfan, comprising busulfan 6.4\u2009mg\/kg (FluBu6.4, <jats:italic>n<\/jats:italic>\u2009=\u2009188) or 9.6\u2009mg\/kg (FluBu9.6, <jats:italic>n<\/jats:italic>\u2009=\u200951). At two years, overall survival (OS) was 68.5%, 57%, and 62.2%, leukemia-free survival (LFS) was 58%, 42.7%, and 45%, relapse incidence (RI) was 27.2%, 40%, and 30.9%, and non-relapse-mortality (NRM) was 23.1%, 20.7%, and 26.8% for patients receiving FluTBI8Gy, FluBu6.4, and FluBu9.6, respectively. In multivariate analysis, the risk of NRM, acute and chronic graft-versus-host disease was not influenced by conditioning. However, RI was higher after FluBu6.4 (hazard ratio [HR] [95% CI]: 1.85 [1.16\u20132.95]), and LFS was lower after both FluBu6.4 (HR: 1.56 [1.09\u20132.23]) and FluBu9.6 (HR: 1.63 [1.02\u20132.58]) as compared to FluTBI8. Although only resulting in a non-significant advantage in OS, this observation indicates a stronger anti-leukemic efficacy of TBI-based intermediate intensity conditioning.<\/jats:p>","DOI":"10.1038\/s41409-023-01966-w","type":"journal-article","created":{"date-parts":[[2023,5,5]],"date-time":"2023-05-05T17:02:07Z","timestamp":1683306127000},"page":"874-880","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Total body irradiation versus busulfan based intermediate intensity conditioning for stem cell transplantation in ALL patients &gt;45 years\u2014a registry-based study by the Acute Leukemia Working Party of the EBMT"],"prefix":"10.1038","volume":"58","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4847-7460","authenticated-orcid":false,"given":"Klaus","family":"Hirschb\u00fchl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4514-4748","authenticated-orcid":false,"given":"Myriam","family":"Labopin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuelle","family":"Polge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5684-9447","authenticated-orcid":false,"given":"Didier","family":"Blaise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean Henri","family":"Bourhis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2114-7533","authenticated-orcid":false,"given":"Gerard","family":"Soci\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8873-2868","authenticated-orcid":false,"given":"Edouard","family":"Forcade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4524-8782","authenticated-orcid":false,"given":"Ibrahim","family":"Yakoub-Agha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9l\u00e8ne","family":"Labussi\u00e8re-Wallet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6052-2618","authenticated-orcid":false,"given":"Wolfgang","family":"Bethge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3142-5581","authenticated-orcid":false,"given":"Patrice","family":"Chevallier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Bonnet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Stelljes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3097-2532","authenticated-orcid":false,"given":"Alexandros","family":"Spyridonidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9458-8025","authenticated-orcid":false,"given":"Zinaida","family":"Peric","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4471-418X","authenticated-orcid":false,"given":"Eolia","family":"Brissot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bipin","family":"Savani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Giebel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7070-487X","authenticated-orcid":false,"given":"Christoph","family":"Schmid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0873-0123","authenticated-orcid":false,"given":"Fabio","family":"Ciceri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0763-1265","authenticated-orcid":false,"given":"Arnon","family":"Nagler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7264-808X","authenticated-orcid":false,"given":"Mohamad","family":"Mohty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,5]]},"reference":[{"key":"1966_CR1","doi-asserted-by":"publisher","first-page":"2389","DOI":"10.1007\/s00277-019-03771-2","volume":"98","author":"S Giebel","year":"2019","unstructured":"Giebel S, Boumendil A, Labopin M, Seesaghur A, Baron F, Ciceri F, et al. Trends in the use of hematopoietic stem cell transplantation for adults with acute lymphoblastic leukemia in Europe: a report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT). Ann Hematol. 2019;98:2389\u201398.","journal-title":"Ann Hematol"},{"key":"1966_CR2","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1038\/s41409-021-01227-8","volume":"56","author":"JR Passweg","year":"2021","unstructured":"Passweg JR, Baldomero H, Chabannon C, Basak GW, de la Camara R, Corbacioglu S, et al. Hematopoietic cell transplantation and cellular therapy survey of the EBMT: monitoring of activities and trends over 30 years. Bone Marrow Transplant. 2021;56:1651\u201364.","journal-title":"Bone Marrow Transplant"},{"key":"1966_CR3","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1002\/ajh.23465","volume":"88","author":"KS Eom","year":"2013","unstructured":"Eom KS, Shin SH, Yoon JH, Yahng SA, Lee SE, Cho BS, et al. Comparable long-term outcomes after reduced-intensity conditioning versus myeloablative conditioning allogeneic stem cell transplantation for adult high-risk acute lymphoblastic leukemia in complete remission. Am J Hematol. 2013;88:634\u201341.","journal-title":"Am J Hematol"},{"key":"1966_CR4","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1038\/leu.2015.230","volume":"30","author":"AG Dinmohamed","year":"2016","unstructured":"Dinmohamed AG, Szab\u00f3 A, van der Mark M, Visser O, Sonneveld P, Cornelissen JJ, et al. Improved survival in adult patients with acute lymphoblastic leukemia in the Netherlands: a population-based study on treatment, trial participation and survival. Leukemia. 2016;30:310\u20137.","journal-title":"Leukemia"},{"key":"1966_CR5","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1111\/ejh.13247","volume":"103","author":"E Lennmyr","year":"2019","unstructured":"Lennmyr E, Karlsson K, Ahlberg L, Garelius H, Huleg\u00e5rdh E, Izarra AS, et al. Survival in adult acute lymphoblastic leukaemia (ALL): a report from the Swedish ALL Registry. Eur J Haematol. 2019;103:88\u201398.","journal-title":"Eur J Haematol"},{"key":"1966_CR6","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/j.bbmt.2005.12.029","volume":"12","author":"DI Marks","year":"2006","unstructured":"Marks DI, Forman SJ, Blume KG, P\u00e9rez WS, Weisdorf DJ, Keating A, et al. A comparison of cyclophosphamide and total body irradiation with etoposide and total body irradiation as conditioning regimens for patients undergoing sibling allografting for acute lymphoblastic leukemia in first or second complete remission. Biol Blood Marrow Transplant: J Am Soc Blood Marrow Transplant. 2006;12:438\u201353.","journal-title":"Biol Blood Marrow Transplant: J Am Soc Blood Marrow Transplant"},{"key":"1966_CR7","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1002\/ajh.25091","volume":"93","author":"A Czyz","year":"2018","unstructured":"Czyz A, Labopin M, Giebel S, Soci\u00e9 G, Apperley J, Volin L, et al. Cyclophosphamide versus etoposide in combination with total body irradiation as conditioning regimen for adult patients with Ph-negative acute lymphoblastic leukemia undergoing allogeneic stem cell transplant: on behalf of the ALWP of the European Society for Blood and Marrow Transplantation. Am J Hematol. 2018;93:778\u201385.","journal-title":"Am J Hematol"},{"key":"1966_CR8","doi-asserted-by":"publisher","first-page":"620.e621","DOI":"10.1016\/j.jtct.2021.03.026","volume":"27","author":"F Khimani","year":"2021","unstructured":"Khimani F, Dutta M, Faramand R, Nishihori T, Perez AP, Dean E, et al. Impact of total body irradiation-based myeloablative conditioning regimens in patients with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation: systematic review and meta-analysis. Transplant Cell Ther. 2021;27:620.e621\u20139.","journal-title":"Transplant Cell Ther"},{"key":"1966_CR9","doi-asserted-by":"publisher","first-page":"4439","DOI":"10.1182\/blood-2010-02-266551","volume":"116","author":"M Mohty","year":"2010","unstructured":"Mohty M, Labopin M, Volin L, Gratwohl A, Soci\u00e9 G, Esteve J, et al. Reduced-intensity versus conventional myeloablative conditioning allogeneic stem cell transplantation for patients with acute lymphoblastic leukemia: a retrospective study from the European Group for Blood and Marrow Transplantation. Blood. 2010;116:4439\u201343.","journal-title":"Blood"},{"key":"1966_CR10","doi-asserted-by":"publisher","first-page":"112972","DOI":"10.18632\/oncotarget.22934","volume":"8","author":"G Roth-Guepin","year":"2017","unstructured":"Roth-Guepin G, Canaani J, Ruggeri A, Labopin M, Finke J, Cornelissen JJ, et al. Allogeneic stem cell transplantation in acute lymphoblastic leukemia patients older than 60 years: a survey from the acute leukemia working party of EBMT. Oncotarget. 2017;8:112972\u20139.","journal-title":"Oncotarget"},{"key":"1966_CR11","unstructured":"Beelen DW, Bug G, Stelljes M, G\u00f6kbuget N, Arnold R. Durchf\u00fchrung der Stammzelltransplantation - Dosisadaptierte Konditionierungstherapie (46-55 Jahre). GMALL-Empfehlungen zur Stammzelltransplantation im Rahmen der Behandlung der akuten lymphatischen Leuk\u00e4mie der Erwachsenen. 2019;4.2:9."},{"key":"1966_CR12","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1038\/sj.bmt.1704776","volume":"35","author":"T Hamaki","year":"2005","unstructured":"Hamaki T, Kami M, Kanda Y, Yuji K, Inamoto Y, Kishi Y, et al. Reduced-intensity stem-cell transplantation for adult acute lymphoblastic leukemia: a retrospective study of 33 patients. Bone Marrow Transplant. 2005;35:549\u201356.","journal-title":"Bone Marrow Transplant"},{"key":"1966_CR13","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.3324\/haematol.2011.040261","volume":"96","author":"R Ram","year":"2011","unstructured":"Ram R, Storb R, Sandmaier BM, Maloney DG, Woolfrey A, Flowers ME, et al. Non-myeloablative conditioning with allogeneic hematopoietic cell transplantation for the treatment of high-risk acute lymphoblastic leukemia. Haematologica. 2011;96:1113\u201320.","journal-title":"Haematologica"},{"key":"1966_CR14","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1002\/ajh.24575","volume":"92","author":"A Rosko","year":"2017","unstructured":"Rosko A, Wang HL, de Lima M, Sandmaier B, Khoury HJ, Artz A, et al. Reduced intensity conditioned allograft yields favorable survival for older adults with B-cell acute lymphoblastic leukemia. Am J Hematol. 2017;92:42\u20139.","journal-title":"Am J Hematol"},{"key":"1966_CR15","doi-asserted-by":"publisher","first-page":"452","DOI":"10.3349\/ymj.2020.61.6.452","volume":"61","author":"SS Lee","year":"2020","unstructured":"Lee SS, Jung SH, Do YR, Kim DS, Lee JH, Park HS, et al. Reduced-intensity conditioning with busulfan and fludarabine for allogeneic hematopoietic stem cell transplantation in acute lymphoblastic leukemia. Yonsei Med J. 2020;61:452\u20139.","journal-title":"Yonsei Med J"},{"key":"1966_CR16","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1038\/s41409-020-0878-5","volume":"55","author":"Z Peric","year":"2020","unstructured":"Peric Z, Labopin M, Peczynski C, Polge E, Cornelissen J, Carpenter B, et al. Comparison of reduced-intensity conditioning regimens in patients with acute lymphoblastic leukemia >45 years undergoing allogeneic stem cell transplantation-a retrospective study by the Acute Leukemia Working Party of EBMT. Bone Marrow Transplant. 2020;55:1560\u20139.","journal-title":"Bone Marrow Transplant"},{"key":"1966_CR17","doi-asserted-by":"publisher","first-page":"153","DOI":"10.2991\/chi.k.210731.001","volume":"3","author":"F Saraceni","year":"2021","unstructured":"Saraceni F, Scortechini I, Fiorentini A, Dubbini MV, Mancini G, Federici I, et al. Conditioning regimens for frail patients with acute leukemia undergoing allogeneic stem cell transplant: how to strike gently. Clin Hematol Int. 2021;3:153\u201360.","journal-title":"Clin Hematol Int"},{"key":"1966_CR18","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1016\/j.bbmt.2005.09.004","volume":"11","author":"AH Filipovich","year":"2005","unstructured":"Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant: J Am Soc Blood Marrow Transplant. 2005;11:945\u201356.","journal-title":"Biol Blood Marrow Transplant: J Am Soc Blood Marrow Transplant"},{"key":"1966_CR19","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","volume":"21","author":"MH Jagasia","year":"2015","unstructured":"Jagasia MH, Greinix HT, Arora M, Williams KM, Wolff D, Cowen EW, et al. National institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. the 2014 diagnosis and staging working group report. Biol Blood Marrow Transplant: J Am Soc Blood Marrow Transplant. 2015;21:389\u2013401.e381.","journal-title":"Biol Blood Marrow Transplant: J Am Soc Blood Marrow Transplant"},{"key":"1966_CR20","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s13045-019-0790-x","volume":"12","author":"J Pavl\u016f","year":"2019","unstructured":"Pavl\u016f J, Labopin M, Niittyvuopio R, Soci\u00e9 G, Yakoub-Agha I, Wu D, et al. Measurable residual disease at myeloablative allogeneic transplantation in adults with acute lymphoblastic leukemia: a retrospective registry study on 2780 patients from the acute leukemia working party of the EBMT. J Hematol Oncol. 2019;12:108.","journal-title":"J Hematol Oncol"},{"key":"1966_CR21","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s43046-020-00042-4","volume":"32","author":"MM Abdelaty","year":"2020","unstructured":"Abdelaty MM, Gawaly A, Fathy GM, Kabbash I, Taha A. Irradiation free conditioning regimen is associated with high relapse rate in Egyptian patients with acute lymphoblastic leukemia following allogeneic hematopoietic stem cell transplantation. J Egypt Natl Cancer Inst. 2020;32:28.","journal-title":"J Egypt Natl Cancer Inst"},{"key":"1966_CR22","doi-asserted-by":"crossref","unstructured":"Marks DI, Stelljes M. Acute Lymphoblastic Leukemia in Adults. In: Enric Carreras CD, Mohamad M, N Kr\u00f6ger (ed.) The EBMT Handbook. Springer Open, 2019, pp 531\u20138.","DOI":"10.1007\/978-3-030-02278-5_71"},{"key":"1966_CR23","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1200\/JCO.20.02529","volume":"39","author":"C Peters","year":"2021","unstructured":"Peters C, Dalle JH, Locatelli F, Poetschger U, Sedlacek P, Buechner J, et al. Total body irradiation or chemotherapy conditioning in childhood ALL: a multinational, randomized, noninferiority phase III study. J Clin Oncol: Off J Am Soc Clin Oncol. 2021;39:295\u2013307.","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"key":"1966_CR24","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1038\/s41409-020-0951-0","volume":"55","author":"Y Akahoshi","year":"2020","unstructured":"Akahoshi Y, Nishiwaki S, Arai Y, Harada K, Najima Y, Kanda Y, et al. Reduced-intensity conditioning is a reasonable alternative for Philadelphia chromosome-positive acute lymphoblastic leukemia among elderly patients who have achieved negative minimal residual disease: a report from the Adult Acute Lymphoblastic Leukemia Working Group of the JSHCT. Bone Marrow Transplant. 2020;55:1317\u201325.","journal-title":"Bone Marrow Transplant"},{"key":"1966_CR25","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.ijrobp.2018.09.002","volume":"103","author":"RW Gao","year":"2019","unstructured":"Gao RW, Weisdorf DJ, DeFor TE, Ehler E, Dusenbery KE. Influence of total body irradiation dose rate on idiopathic pneumonia syndrome in acute leukemia patients undergoing allogeneic hematopoietic cell transplantation. Int J Radiat Oncol Biol Phys. 2019;103:180\u20139.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1966_CR26","doi-asserted-by":"publisher","first-page":"708906","DOI":"10.3389\/fonc.2021.708906","volume":"11","author":"J Vogel","year":"2021","unstructured":"Vogel J, Hui S, Hua CH, Dusenbery K, Rassiah P, Kalapurakal J, et al. Pulmonary toxicity after total body irradiation - critical review of the literature and recommendations for toxicity reporting. Front Oncol. 2021;11:708906.","journal-title":"Front Oncol"},{"key":"1966_CR27","doi-asserted-by":"publisher","first-page":"5640","DOI":"10.3390\/cancers13225640","volume":"13","author":"M Oertel","year":"2021","unstructured":"Oertel M, Martel J, Mikesch JH, Scobioala S, Reicherts C, Kr\u00f6ger K, et al. The burden of survivorship on hematological patients-long-term analysis of toxicities after total body irradiation and allogeneic stem cell transplantation. Cancers. 2021;13:5640.","journal-title":"Cancers"},{"key":"1966_CR28","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1007\/s12185-021-03282-9","volume":"115","author":"M Onizuka","year":"2022","unstructured":"Onizuka M, Fujii N, Nakasone H, Ogata M, Atsuta Y, Suzuki R, et al. Risk factors and prognosis of non-infectious pulmonary complications after allogeneic hematopoietic stem cell transplantation. Int J Hematol. 2022;115:534\u201344.","journal-title":"Int J Hematol"},{"key":"1966_CR29","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/s41409-020-01050-7","volume":"56","author":"S Giebel","year":"2021","unstructured":"Giebel S, Labopin M, Sobczyk-Kruszelnicka M, Stelljes M, Byrne JL, Fegueux N, et al. Total body irradiation + fludarabine compared to busulfan + fludarabine as \u201creduced-toxicity conditioning\u201d for patients with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation in first complete remission: a study by the Acute Leukemia Working Party of the EBMT. Bone Marrow Transplant. 2021;56:481\u201391.","journal-title":"Bone Marrow Transplant"},{"key":"1966_CR30","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1200\/JCO.22.00767","volume":"41","author":"H Zhang","year":"2023","unstructured":"Zhang H, Fan Z, Huang F, Han L, Xu Y, Xu N, et al. Busulfan plus cyclophosphamide versus total body irradiation plus cyclophosphamide for adults acute B lymphoblastic leukemia: an open-label, multicenter, phase III trial. J Clin Oncol: Off J Am Soc Clin Oncol. 2023;41:343\u201353.","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"key":"1966_CR31","doi-asserted-by":"publisher","first-page":"e812","DOI":"10.1097\/HS9.0000000000000812","volume":"7","author":"A Spyridonidis","year":"2023","unstructured":"Spyridonidis A, Labopin M, Savani B, Giebel S, Bug G, Sch\u00f6nland S, et al. Reduced 8-gray compared to standard 12-gray total body irradiation for allogeneic transplantation in first remission acute lymphoblastic leukemia: a study of the acute leukemia working party of the EBMT. HemaSphere. 2023;7:e812.","journal-title":"HemaSphere"},{"key":"1966_CR32","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1182\/blood-2015-03-636548","volume":"126","author":"DY Kim","year":"2015","unstructured":"Kim DY, Joo YD, Lim SN, Kim SD, Lee JH, Lee JH, et al. Nilotinib combined with multiagent chemotherapy for newly diagnosed Philadelphia-positive acute lymphoblastic leukemia. Blood. 2015;126:746\u201356.","journal-title":"Blood"},{"key":"1966_CR33","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1016\/S1470-2045(15)00207-7","volume":"16","author":"E Jabbour","year":"2015","unstructured":"Jabbour E, Kantarjian H, Ravandi F, Thomas D, Huang X, Faderl S, et al. Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study. Lancet Oncol. 2015;16:1547\u201355.","journal-title":"Lancet Oncol"},{"key":"1966_CR34","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1182\/bloodadvances.2016001495","volume":"1","author":"F Ravandi","year":"2016","unstructured":"Ravandi F, Othus M, O\u2019Brien SM, Forman SJ, Ha CS, Wong JYC, et al. US intergroup study of chemotherapy plus dasatinib and allogeneic stem cell transplant in philadelphia chromosome positive ALL. Blood Adv. 2016;1:250\u20139.","journal-title":"Blood Adv"},{"key":"1966_CR35","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.3324\/haematol.2016.144535","volume":"101","author":"S Chiaretti","year":"2016","unstructured":"Chiaretti S, Vitale A, Vignetti M, Piciocchi A, Fazi P, Elia L, et al. A sequential approach with imatinib, chemotherapy and transplant for adult Ph+ acute lymphoblastic leukemia: final results of the GIMEMA LAL 0904 study. Haematologica. 2016;101:1544\u201352.","journal-title":"Haematologica"},{"key":"1966_CR36","doi-asserted-by":"crossref","unstructured":"Giebel S, Czyz A, Ottmann O, Baron F, Brissot E, Ciceri F, et al. Use of tyrosine kinase inhibitors to prevent relapse after allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: a position statement of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Cancer. 2016;122:2941\u201351.","DOI":"10.1002\/cncr.30130"},{"key":"1966_CR37","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1038\/s41409-020-01173-x","volume":"56","author":"K Hirschb\u00fchl","year":"2021","unstructured":"Hirschb\u00fchl K, Labopin M, Houhou M, Gabellier L, Labussi\u00e8re-Wallet H, Lioure B, et al. Second- and third-generation tyrosine kinase inhibitors for Philadelphia-positive adult acute lymphoblastic leukemia relapsing post allogeneic stem cell transplantation-a registry study on behalf of the EBMT Acute Leukemia Working Party. Bone Marrow Transplant. 2021;56:1190\u20139.","journal-title":"Bone Marrow Transplant"},{"key":"1966_CR38","doi-asserted-by":"crossref","unstructured":"Bazarbachi A, Labopin M, Aljurf M, Niittyvuopio R, Balsat M, Blaise D, et al. 20-year steady increase in survival of adult patients with relapsed philadelphia-positive acute lymphoblastic leukemia post allogeneic hematopoietic cell transplantation. Clin Cancer Res. 2022;28:1004\u201312.","DOI":"10.1158\/1078-0432.CCR-21-2675"},{"key":"1966_CR39","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1007\/s11899-018-0462-x","volume":"13","author":"JT Leonard","year":"2018","unstructured":"Leonard JT, Hayes-Lattin B. Reduced intensity conditioning allogeneic hematopoietic stem cell transplantation for acute lymphoblastic leukemia; current evidence, and improving outcomes going forward. Curr Hematol Malig Rep. 2018;13:329\u201340.","journal-title":"Curr Hematol Malig Rep"},{"key":"1966_CR40","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1038\/s41375-021-01135-2","volume":"35","author":"J Esteve","year":"2021","unstructured":"Esteve J, Giebel S, Labopin M, Czerw T, Wu D, Volin L, et al. Allogeneic hematopoietic stem cell transplantation for adult patients with t(4;11)(q21;q23) KMT2A\/AFF1 B-cell precursor acute lymphoblastic leukemia in first complete remission: impact of pretransplant measurable residual disease (MRD) status. An analysis from the Acute Leukemia Working Party of the EBMT. Leukemia. 2021;35:2232\u201342.","journal-title":"Leukemia"},{"key":"1966_CR41","doi-asserted-by":"publisher","first-page":"130","DOI":"10.2991\/chi.k.211119.001","volume":"3","author":"F Fernando","year":"2021","unstructured":"Fernando F, Robertson HF, El-Zahab S, Pavl\u016f J. How I use measurable residual disease in the clinical management of adult acute lymphoblastic leukemia. Clin Hematol Int. 2021;3:130\u201341.","journal-title":"Clin Hematol Int"},{"key":"1966_CR42","doi-asserted-by":"publisher","first-page":"6963","DOI":"10.1182\/blood-2011-01-332007","volume":"117","author":"RJ Soiffer","year":"2011","unstructured":"Soiffer RJ, Lerademacher J, Ho V, Kan F, Artz A, Champlin RE, et al. Impact of immune modulation with anti-T-cell antibodies on the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies. Blood. 2011;117:6963\u201370.","journal-title":"Blood"},{"key":"1966_CR43","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1016\/j.bbmt.2010.05.005","volume":"16","author":"EP Alyea","year":"2010","unstructured":"Alyea EP, DeAngelo DJ, Moldrem J, Pagel JM, Przepiorka D, Sadelin M, et al. NCI first international workshop on the biology, prevention and treatment of relapse after allogeneic hematopoietic cell transplantation: report from the committee on prevention of relapse following allogeneic cell transplantation for hematologic malignancies. Biol Blood Marrow Transplant: J Am Soc Blood Marrow Transplant. 2010;16:1037\u201369.","journal-title":"Biol Blood Marrow Transplant: J Am Soc Blood Marrow Transplant"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41409-023-01966-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-023-01966-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-023-01966-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,3]],"date-time":"2023-08-03T08:03:29Z","timestamp":1691049809000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-023-01966-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,5]]},"references-count":43,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["1966"],"URL":"https:\/\/doi.org\/10.1038\/s41409-023-01966-w","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,5]]},"assertion":[{"value":"28 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}